Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (T2DM) for at least 1 year~* At least 18 years of age~* Using metformin and/or sulfonylurea(s) with once daily glargine or NPH for at least 3 months prior to the study. Prestudy dose requirements: insulin dose maximum 1.0 unit/kilogram/day (U/kg/day). Oral antihyperglycemic medications (OAMs): Metformin dose at least 1500 milligram/day (mg/day) and/or sulfonylurea dose at least half the maximum daily dose specified in the local package insert. OAM doses stable for 6 weeks prior to the study.~* Hemoglobin A1c (HbA1c) less than or equal to 10.5% before randomization~* Body Mass Index (BMI) 19 to 45 kilogram/square meter (kg/m²)~* Capable and willing to prepare and inject insulin with a syringe while continuing to use the prestudy OAMs, monitor own blood glucose; complete the study diary; be receptive to diabetes education; comply with study visits and receive telephone calls between visits~* Women of childbearing potential must test negative for pregnancy before receiving treatment and agree to use reliable birth control until completing the follow-up visit~Exclusion Criteria:~* Long-term use of short- or rapid-acting or premixed insulin within the 6 months before the study. Short-term insulin therapy or occasional use are permitted~* Use of any glucose-lowering medications not allowed by the inclusion criteria in the 3 months before entry into the study~* Use of prescription or over-the-counter medications to promote weight loss within 3 months before entry into the study~* Current participation in a weight loss program, or plans to do so during the study~* Treatment with any antibody-based therapy within 6 months prior to the study~* Use of chronic (\>14 consecutive days) systemic glucocorticoid therapy currently or within 4 weeks prior to the study~* More than 1 episode of severe hypoglycemia within 6 months prior to the study, or currently diagnosed with hypoglycemia unawareness~* 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months preceding the study~* Liver disease~* History of renal transplantation, current renal dialysis, or creatinine \>2.0 milligram/deciliter (mg/dL) (177 micromole/Liter \[μmol\]/L)~* Cardiac disease with a marked impact on physical functioning~* Clinically significant electrocardiogram (ECG) abnormalities at screening~* Malignancy other than basal cell or squamous cell skin cancer~* Fasting triglycerides \>500 mg/dL~* Known diabetic autonomic neuropathy~* Known hypersensitivity or allergy to study insulin or its excipients~* Blood transfusion or severe blood loss within 3 months prior to entry into the study or known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the HbA1c methodology~* Irregular sleep/wake cycle~* Women who are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2605541 Dosing Algorithm 1 (Type: EXPERIMENTAL): Participants took both LY2605541 and their pre-study insulin for first several days
- LY2605541 Dosing Algorithm 2 (Type: EXPERIMENTAL): Participants took only LY2605541 with first dose doubled
- Insulin glargine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).